One would expect, therefore, limited consequences of FKN inhibition in healthy tissues, or immune suppression, such as with IL-1 or IL-6 inhibition, and a more focused diminution of the inflammatory reaction to MI or CAD in general. This evidence concerns the gene IL6 and coronary artery disorder.